The estimated Net Worth of Guillaume Cerutti is at least $598 Thousand dollars as of 15 June 2017. Guillaume Cerutti owns over 26,560 units of Avadel Pharmaceuticals plc stock worth over $319,956 and over the last 8 years Guillaume sold AVDL stock worth over $277,818.
Guillaume has made over 1 trades of the Avadel Pharmaceuticals plc stock since 2017, according to the Form 4 filled with the SEC. Most recently Guillaume sold 26,560 units of AVDL stock worth $277,818 on 15 June 2017.
The largest trade Guillaume's ever made was selling 26,560 units of Avadel Pharmaceuticals plc stock on 15 June 2017 worth over $277,818. On average, Guillaume trades about 5,312 units every 0 days since 2016. As of 15 June 2017 Guillaume still owns at least 23,440 units of Avadel Pharmaceuticals plc stock.
You can see the complete history of Guillaume Cerutti stock trades at the bottom of the page.
Guillaume's mailing address filed with the SEC is C/O FLAMEL TECHNOLOGIES S.A., 33 AVENUE DU DR. GEORGES LEVY, VENISSIEUX, I0, 69200.
Over the last 8 years, insiders at Avadel Pharmaceuticals plc have traded over $7,791,038 worth of Avadel Pharmaceuticals plc stock and bought 775,568 units worth $4,366,224 . The most active insiders traders include Healthcare Master Fund Ltd ..., Kevin Broadfin Capital, Llc..., and Naseem Amin. On average, Avadel Pharmaceuticals plc executives and independent directors trade stock every 43 days with the average trade being worth of $381,436. The most recent stock trade was executed by Thomas S Mchugh on 16 January 2024, trading 2,000 units of AVDL stock currently worth $29,000.
avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.
Avadel Pharmaceuticals plc executives and other stock owners filed with the SEC include: